Detection of C-ERBB-2 Related Protein in Sera from Breast Cancer Patients Relationship to ERBB2 gene amplification and c-erbB-2 protein overexpression in tumour

References

• Coussens L, Yang-Feng T L, Liao Y-C, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985; 230: 1132–9
   PubMed Web of Science ®Google Scholar
• King C R, Kraus M H, Aaronson S A. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 1985; 229: 974–8
   PubMed Web of Science ®Google Scholar
• Semba K, Kamata N, Toyoshima K, Yamamoto T. A v-erbB-related protooncogene, ERBB2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma. Proc Natl Acad Sci USA 1985; 82: 6497–501
   PubMed Web of Science ®Google Scholar
• Schechter A L, Stern D F, Vaidyanathan L, et al. The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature 1984; 312: 513–6
   PubMed Web of Science ®Google Scholar
• Lupu R, Colomer R, Zugmaier G, et al. Direct interaction of a ligand for the erbB2 oncogene product with the EGF receptor and p185erbB2. Science 1990; 249: 1552–5
   PubMed Web of Science ®Google Scholar
• Yarden Y, Weinberg R A. Experimental approaches to hypothetical hormones: detection of a candidate ligand of the neu protooncogene. Proc Natl Acad Sci USA 1989; 86: 3179–83
   PubMed Web of Science ®Google Scholar
• Huang S S, Koh H A, Konish Y, Bullock L D, Huang S J. Differential processing and turnover of the oncogenically activated neu/erbB2 gene product and its normal cellular counterpart. J Biol Chem 1990; 265: 3340–6
   PubMed Web of Science ®Google Scholar
• Dobashi K, Davis J G, Mikami Y, Freeman J K, Hamuro J, Greene M I. Characterization of a neu/c-erbB-2 protein-specific activating factor. Proc Natl Acad Sci USA 1991; 88: 8582–6
   PubMed Web of Science ®Google Scholar
• Tarakhovsky A, Zaichuk T, Prassolov V, Butenko Z A. A 25 kDa polypeptide is the ligand for p185neu and is secreted by activated macrophages. Oncogene 1991; 6: 2187–96
   PubMed Web of Science ®Google Scholar
• Yarden Y, Peles E. Biochemical analysis of the ligand for the neu oncogenic receptor. Biochemistry 1991; 30: 3543–50
   PubMed Web of Science ®Google Scholar
• Orr-Urtreger A, Trakhtenbrot L, Ben-Levy R, et al. Neural expression and chromosomal mapping of Neu differentiation factor to 8p12-p21. Proc Natl Acad Sci USA 1993; 90: 1867–71
   PubMed Web of Science ®Google Scholar
• Bachus S S, Gudkov A V, Zelnick C R, et al. Neu differentiation factor (heregulin) induces expression of intracellular adhesion molecule 1: Implications for mammary tumors. Cancer Res 1993; 53: 5251–61
   PubMed Web of Science ®Google Scholar
• Lemoine N R, Staddon S, Dickson C, Barnes D M, Gullick W J. Absence of activating transmembrane mutations in the c-erbB-2 protooncogene in human breast cancer. Oncogene 1990; 5: 237–9
   PubMed Web of Science ®Google Scholar
• Slamon D J, Clark G M, Wong S G, Levin W J, Ullrich A, McGuire W L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177–82
   PubMed Web of Science ®Google Scholar
• Zhou D-J, Ahuja H, Cline M J. Proto-oncogene abnormalities in human breast cancer: c-ERBB-2 amplification does not correlate with recurrence of disease. Oncogene 1989; 4: 105–8
   PubMed Web of Science ®Google Scholar
• Børresen A-L, Ottestad L, Gaustad A, et al. Amplification and protein over-expression of the neu/HER-2/c-erbB-2 protooncogene in human breast carcinomas: relationship to loss of gene sequences on chromosome 17, family history and prognosis. Br J Cancer 1990; 62: 585–90
   PubMed Web of Science ®Google Scholar
• Zhou D, Battifora H, Yokota J, Yamamoto T, Cline M J. Association of multiple copies of the c-erbB-2 oncogene with spread of breast cancer. Cancer Res 1987; 47: 6123–5
   PubMed Web of Science ®Google Scholar
• Falck V G, Gullick W J. c-erbB-2 oncogene product staining in gastric adenocarcinoma. An immunohistochemical study. J Pathol 1989; 159: 107–11
   PubMed Web of Science ®Google Scholar
• Slamon D J, Godolphin W, Jones L A, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707–12
   PubMed Web of Science ®Google Scholar
• Berchuck A, Kamel A, Whitaker R, et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res. 1990; 50: 4087–91
   PubMed Web of Science ®Google Scholar
• Borg Å, Tandon A K, Sigurdsson H, et al. HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 1990; 50: 4332–7
   PubMed Web of Science ®Google Scholar
• Paterson M C, Dietrich K D, Danyluk J, et al. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer. Cancer Res 1991; 51: 556–67
   PubMed Web of Science ®Google Scholar
• Lovekin C, Ellis I O, Locker A, et al. c-erbB-2 oncoprotein expression in primary and advanced breast cancer. Br J Cancer 1991; 63: 439–43
   PubMed Web of Science ®Google Scholar
• Winstanley J, Cooke T, Murray G D, et al. The long term prognostic significance of c-erbB-2 in primary breast cancer. Br J Cancer 1991; 63: 447–50
   PubMed Web of Science ®Google Scholar
• Muss H B, Thor A D, Berry D A, et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994; 330: 1260–6
   PubMed Web of Science ®Google Scholar
• Carney W P, Hamer P J, Petit D, et al. Detection and quantitation of the human neu oncoprotein. Tumor Marker Oncology 1991; 6: 53–72
   Google Scholar
• Sias P E, Kotts C E, Vetterlein D, Shepard M, Wong W LT. ELISA for quantitation of the extracellular domain of p185her2 in biological fluids. J Immunol Methods 1990; 132: 73–80
   PubMed Web of Science ®Google Scholar
• Mori S, Mori Y, Mukaiyama T, et al. In vitro and in vivo release of soluble erbB-2 protein from human carcinoma cells. Jpn J Cancer Res 1990; 81: 489–94
   PubMedGoogle Scholar
• Zabrecky J R, Lam T, McKenzie S J, Carney W. The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, SK-BR-3. J Biol Chem 1991; 266: 1716–20
   PubMed Web of Science ®Google Scholar
• McKenzie S J, Marks P J, Lam T, et al. Generation and characterization of monoclonal antibodies specific for the human neu oncogeneproduct, p185. Oncogene 1989; 4: 543–8
   PubMed Web of Science ®Google Scholar
• DiFiore P P, Pierce J H, Kraus M H, Segatto O, King C R, Aaronson S A. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 1987; 237: 178–82
   PubMed Web of Science ®Google Scholar
• Bargmann C I, Hung M C, Weinberg R A. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell 1987; 45: 649–57
   Web of Science ®Google Scholar
• Nesland J M, Ottestad L, Børresen A-L, et al. The c-erbB-2 protein in primary and metastatic breast carcinomas. Ultrastruct Pathol 1991; 15: 281–9
   PubMed Web of Science ®Google Scholar
• Kandl H, Seymour L, Bezwoda W R. Soluble c-erbB-2 fragment in serum correlates with disease stage and predicts for shortened survival in patients with early-stage and advanced breast cancer. Br J Cancer 1994; 70: 739–42
   PubMed Web of Science ®Google Scholar
• Shepard H M, Lewis G D, Sarup J C, et al. Monoclonal antibody therapy of human cancer-taking the HER2 protooncogene to the clinic. J Clin Immunol 1991; 11: 117–27
   PubMed Web of Science ®Google Scholar